Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA.
Cheah CY, et al.
Ann Oncol. 2016 Jul;27(7):1317-23. doi: 10.1093/annonc/mdw169. Epub 2016 Apr 18.
Ann Oncol. 2016.
PMID: 27091808
Free PMC article.